Letermovir to prevent CMV in new heart transplant patients
Part of Heart & circulation, Infections clinical trials.
This Phase 2 trial tests whether the medicine letermovir can prevent a common viral infection (CMV) after a new heart transplant. It may help reduce CMV infection or illness in people who are at moderate to high CMV risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You recently had a heart transplant (a new transplant).
- Your CMV blood test shows you are at moderate or high risk (D+/R+ or D-/R+ or D+/R-).
- You are not currently dealing with an active CMV infection or CMV disease.
- You have not needed short-term mechanical heart support before your transplant, and this is not a re-transplant.
- You must not be pregnant, and you must not be allergic to letermovir (or valganciclovir).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This study tests a drug called letermovir to prevent CMV infection after a kidney or liver transplant. It is for adults at moderate risk of CMV and may help keep you healthy after surgery.
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Hear when a new CMV Viremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.